As per MRFR analysis, the alpha mannosidosis market size was estimated at 6.44 (USD Billion) in 2022. The alpha mannosidosis market industry is expected to grow from 7.01(USD Billion) in 2023 to 15.0 (USD Billion) by 2032. The alpha mannosidosis market CAGR (growth rate) is expected to be around 8.82% during the forecast period (2024-2032).
The alpha mannosidosis market is poised for significant growth, driven by factors such as rising prevalence of rare genetic disorders, increasing awareness about the condition, and advancements in gene therapy. The advent of gene therapy holds immense promise for treating this debilitating condition, offering hope to patients and their families.
Key trends in the alpha mannosidosis market include the growing demand for early diagnosis and treatment, the emergence of novel therapeutic approaches, and the increasing role of patient support groups. With the continued focus on research and development, the market is expected to witness the introduction of new and innovative therapies, further expanding treatment options for patients. Moreover, increasing collaboration between researchers, clinicians, and pharmaceutical companies is driving advancements and facilitating the development of effective treatments for alpha mannosidosis.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Alpha-mannosidosis is a rare inherited lysosomal storage disorder (LSD) caused by a deficiency of the enzyme alpha-mannosidase. The rising prevalence of LSDs, including alpha-mannosidosis, is a major driver of market growth.
According to a study published in the journal Molecular Genetics & Metabolism, the global prevalence of LSDs is estimated to be around 1 in 5,000 live births. This increasing prevalence is attributed to factors such as improved diagnostic techniques, increased awareness of LSDs among healthcare professionals, and the availability of newborn screening programs.
As the number of individuals diagnosed with alpha-mannosidosis and other LSDs continues to rise, the demand for effective treatments and therapies is expected to drive the growth of the Global Alpha Mannosidosis Market.
Enzyme replacement therapy (ERT) is a treatment option for alpha-mannosidosis that involves the administration of the missing enzyme, alpha-mannosidase. Technological advancements in ERT have led to the development of more effective and targeted therapies.
For example, the use of recombinant DNA technology has enabled the production of highly purified and stable forms of alpha-mannosidase. These advancements have improved the efficacy and safety of ERT, making it a more viable treatment option for patients with alpha-mannosidosis. As ERT continues to evolve, it is expected to remain a key driver of growth in the Global Alpha Mannosidosis Market.
One of the main drivers of the market is the government’s initiatives and grants. The governments all around the world have realized that there are many unmet medical needs of people affected with rare diseases, and for this reason they have started to launch programs and policies that support research, development, and provision of treatment. In the US, the Orphan Drug Act supports pharmaceutical companies that develop drugs against rare conditions, including alpha-mannosidosis.
Government grants for conducting research and running clinical trials for new treatment methods have also initiated industry’s growth. Hence, as governments continue to pay attention to rare diseases, the Alpha Mannosidosis Market will continue to benefit from the government’s funds and new initiatives.
The Alpha Mannosidosis Market is segmented based on treatment type into enzyme replacement therapy, gene therapy, and other therapies. Among these segments, the enzyme replacement therapy segment is expected to dominate the Alpha Mannosidosis Market and represent a market share of 60.2% in 2023.
Enzyme replacement therapy is the most largely accepted treatment and approved for use in management of symptoms. For example, in the year 2003, laronidase, under the trade name Aldurazyme, was approved for use in the management of mild to moderate forms of alpha mannosidosis.
The gene therapy segment is expected to register a CAGR of 12.5% and secondly in line to dominate the market. Other therapies account for a smaller share, these are only supportive care places provided. In advanced cases, physical therapy is suggested but will offer little benefit in the case of severely affected individuals.
The Alpha Mannosidosis Market is expected to register a stupendous growth rate over the forecast period, owing to the increasing prevalence of the disease, an increase in the adoption of symptomatic treatment and the availability of antecedents to treat the condition.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Alpha Mannosidosis Market segmentation by severity consists of infantile-onset, late-onset, and juvenile-onset. The infantile-onset segment held the largest revenue share of 45% in 2023 and is expected to maintain its dominance throughout the forecast period. This can be attributed to the severe symptoms and early onset of the disease in this segment.
The late-onset segment is projected to grow at a significant CAGR of 9.2% during the forecast period, owing to the increasing awareness and improved diagnosis of the disease. The juvenile-onset segment is expected to witness a steady growth, with a CAGR of 8.6% from 2023 to 2032. The Alpha Mannosidosis Market is expected to reach a valuation of 15.0 USD Billion by 2032, expanding at a CAGR of 8.82% during the forecast period 2023-2032.
The Alpha Mannosidosis Market is segmented by age group into children and adults. The children segment accounted for a larger share of the market in 2023 and is projected to continue to grow at a faster rate during the forecast period. This is due to the higher incidence of Alpha Mannosidosis in children, as well as the earlier onset of symptoms.
The adults’ segment is also expected to grow, but at a slower rate, as the population of adults with alpha mannosidosis increases. In 2023, the Alpha Mannosidosis Market was valued at 7.01 billion USD. The growth of the market is attributed to the increasing prevalence of alpha mannosidosis, the development of new treatments, and the rising awareness of the disease.
The End-Use segment of the Alpha Mannosidosis Market plays a crucial role in shaping market dynamics. Hospitals, clinics, and home care settings are the primary end-users of Alpha Mannosidosis treatments and services, driving significant market growth. In 2023, the hospital segment accounted for the largest share of the market, owing to the comprehensive medical infrastructure and advanced treatment facilities available in hospitals.
The Alpha Mannosidosis Market revenue in the hospital segment is projected to reach USD 6.1 billion by 2032, exhibiting a CAGR of 8.5%.Clinics also contribute significantly to market growth, providing specialized care and support to patients with Alpha Mannosidosis. The home care segment is gaining traction as patients seek convenient and cost-effective treatment options. As home care services expand and technology advances, this segment is expected to witness notable growth in the coming years.
The Alpha Mannosidosis Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023, and is expected to continue to dominate the market during the forecast period. The growth of the Alpha Mannosidosis Market in North America can be attributed to the increasing prevalence of the disease, the availability of advanced treatment options, and the presence of a large number of pharmaceutical and biotechnology companies in the region. Europe is the second-largest market for Alpha Mannosidosis, followed by APAC.
The APAC region is expected to witness the fastest growth in the market during the forecast period, due to the increasing awareness of the disease and the growing demand for effective treatment options. South America and MEA are expected to account for a smaller share of the Alpha Mannosidosis Market during the forecast period.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Major players in the alpha mannosidosis market are continuously focusing on developing innovative products and expanding their global reach to cater to the growing patient population. They are also actively involved in research and development activities to improve the treatment outcomes for patients with Alpha Mannosidosis.
Leading alpha mannosidosis market players are adopting various strategies such as mergers and acquisitions, partnerships, and collaborations to strengthen their market position and gain a competitive advantage. The alpha mannosidosis market development is being driven by the increasing prevalence of the disease, rising awareness about the condition, and advancements in therapeutic options. However, the high cost of treatment and limited access to therapies in certain regions pose challenges to the growth of the market.
BioMarin Pharmaceutical Inc. is a leading player in the Alpha Mannosidosis Market. The company is committed to developing and commercializing innovative therapies for rare genetic diseases. BioMarin's portfolio includes VIMIZIM (elosulfase alfa), an enzyme replacement therapy for the treatment of Alpha Mannosidosis. The company has a strong global presence and is actively involved in clinical research to expand the indications for VIMIZIM.
Another key player in the Alpha Mannosidosis Market is Amicus Therapeutics. The company is focused on developing and commercializing therapies for rare metabolic diseases. Amicus's pipeline includes AT-GAA (cipaglucosidase alfa), an investigational enzyme replacement therapy for the treatment of Alpha Mannosidosis. The company is actively engaged in clinical trials to evaluate the safety and efficacy of AT-GAA and plans to submit a marketing application for the therapy in the near future.
Key Companies in the Alpha Mannosidosis Market Include:
The Alpha Mannosidosis Market is anticipated to reach a value of USD 15.0 billion by 2032, expanding at a CAGR of 8.82% from 2024 to 2032. The rising prevalence of lysosomal storage disorders and the increasing awareness of alpha mannosidosis are key factors driving market growth. Additionally, the development of novel therapies, such as enzyme replacement therapy and gene therapy, is expected to create significant growth opportunities in the coming years.
Key players operating in the market include BioMarin Pharmaceutical Inc., Amicus Therapeutics, Inc., and Chiesi Farmaceutici S.p.A. Recent developments in the market include the approval of Lumizyme (alglucosidase alfa) for the treatment of Alpha Mannosidosis in the United States and Europe. Continued research and development efforts are expected to further expand the treatment options and improve the quality of life for patients with Alpha Mannosidosis.
| Report Attribute/Metric | Details |
| Market Size 2022 | 6.44 (USD Billion) |
| Market Size 2023 | 7.01 (USD Billion) |
| Market Size 2032 | 15.0 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 8.82% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Intellia Therapeutics, Inc., Amicus Therapeutics, Genzyme Corporation, Sanofi Genzyme, Sangamo Therapeutics, Inc., Editas Medicine, Inc., Orchard Therapeutics, Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Regeneron Pharmaceuticals, Inc., Shire plc, Ultragenyx Pharmaceutical Inc., Zealand Pharma A/S, CRISPR Therapeutics AG, Protalix BioTherapeutics, Inc. |
| Segments Covered | Treatment Type, Severity, Age Group, End-Use, Regional |
| Key Market Opportunities | Growing awareness of AM Advancements in gene therapy Orphan drug designation and incentives Rise in publicprivate funding and Expanding research and development initiatives |
| Key Market Dynamics | Growing awareness rising prevalence favorable reimbursement policies increasing RampD investment advancements in gene therapy |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Alpha Mannosidosis Market is expected to exhibit a CAGR of 8.82% from 2023 to 2032.
The Alpha Mannosidosis Market is projected to reach a valuation of USD 15.0 billion by 2032.
North America is expected to dominate the Alpha Mannosidosis Market throughout the forecast period.
Rising prevalence of genetic disorders and increasing government support for research and development are driving the growth of the Global Alpha Mannosidosis Market.
Key players in the Alpha Mannosidosis Market include BioMarin Pharmaceutical Inc., Genzyme Corporation, and Shire plc.
Alpha Mannosidosis is primarily used in the treatment of genetic disorders such as Alpha-Mannosidosis.
The Alpha Mannosidosis Market is valued at USD 7.01 billion in 2023.
Asia Pacific is expected to witness the highest growth rate in the Global Alpha Mannosidosis Market.
High cost of treatment and lack of awareness about the disease are major challenges faced by the Global Alpha Mannosidosis Market.
Technological advancements and increasing research activities present significant growth opportunities in the Global Alpha Mannosidosis Market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
